Skip to main content
Adaptimmune Therapeutics PLC logo

Adaptimmune Therapeutics PLC — Investor Relations & Filings

Ticker · ADAP ISIN · US00653A1079 LEI · 549300UUNWK8TRT5EW12 US Manufacturing
Open in API
Filings indexed 807 across all filing types
Latest filing 2019-08-08 Director's Dealing
Country GB United Kingdom
Listing US ADAP

About Adaptimmune Therapeutics PLC

https://www.adaptimmune.com/

Adaptimmune Therapeutics is a commercial-stage biopharmaceutical company specializing in the development of novel T-cell receptor (TCR) T-cell therapies for cancer. The company utilizes a proprietary platform to engineer a patient's own T-cells to recognize and fight solid tumors. Its first FDA-approved therapy, Tecelra (afami-cel), is a treatment for advanced synovial sarcoma. Adaptimmune is advancing a robust pipeline of cell therapies, including preclinical programs targeting PRAME and CD70, as well as an allogeneic platform. The company's mission is to deliver transformative, potentially single-infusion treatments to reshape cancer care for patients with difficult-to-treat solid tumors.

Recent filings

Filing Released Lang Actions
4
Director's Dealing
2019-08-08 English
4
Director's Dealing
2019-08-06 English
3
Director's Dealing
2019-08-06 English
10-Q
Interim / Quarterly Report Q2 2019
2019-08-01 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 1, 2019, reporting the issuance of a press release announcing financial results for the second quarter ended June 30, 2019. The text states that the press release is attached as Exhibit 99.1 and incorporated by reference. The document itself does not contain the financial results but announces their release. The length is 3849 characters, which is relatively short and consistent with an announcement rather than a full report. According to the MENU VS MEAL RULE, this is an announcement of a report, not the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement of financial results without substantive financial data included in the text.
2019-08-01 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated July 27, 2019, reporting changes in the company's board and senior management. It details the departure of a director/officer and the appointment of a new executive officer, including employment terms. The content focuses on management changes and related agreements, with no financial statements or earnings data. Therefore, it fits the category of Board/Management Information (MANG). The document length (8448 characters) supports it being a full report rather than a brief announcement or certification.
2019-08-01 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.